ADMET Screening

In-silico ADMET risk and developability triage for CNS-oriented human small-molecule lead candidates.

Try a known compound
11 ADMET endpoints 5 hard gates 4 pillar scores Human small-molecule scope
See a sample report (amiodarone) →
What's covered

4 Pillar Scores

  • Safety Liability — hERG + CYP inhibition liabilities
  • CNS Exposure — BBB permeability, P-gp substrate likelihood, and compatibility with practical CNS small-molecule exposure space
  • PK / Distribution — PPB, Vdss, half-life
  • Developability — aqueous solubility, logD7.4

5 Hard Gates

  • Cardiac Safety (hERG) — flags strong hERG inhibitors
  • CYP / DDI Safety — flags broad CYP inhibition patterns
  • CNS Access — BBB, P-gp, and physicochemical minimum for CNS programs
  • PK Sanity — flags distribution or exposure profiles incompatible with preferred CNS lead behavior
  • Developability Floor — flags extreme logD7.4 / solubility issues, or blocking chemical realism liabilities
Starting Chemical Realism checks...